Shukra Pharmaceuticals is currently showing signs of bullish intent after breaking out of a well-defined consolidation range. The stock formed a series of higher lows, indicating accumulating buying pressure, and recently broke above a key resistance level with strong momentum.
The breakout candle was large and decisive, closing near its high, which signals confidence among buyers. Following the breakout, price has started to establish a new base just above the previous resistance — now acting as support — a classic sign of strength and trend continuation.
Volume during the breakout session was notably higher than recent averages, reinforcing the conviction behind the move. Any shallow pullbacks toward the breakout zone or previous consolidation highs can provide low-risk buying opportunities.
If the current structure continues, the next leg higher may test prior supply zones or unfilled gaps visible on the left side of the chart.
The breakout candle was large and decisive, closing near its high, which signals confidence among buyers. Following the breakout, price has started to establish a new base just above the previous resistance — now acting as support — a classic sign of strength and trend continuation.
Volume during the breakout session was notably higher than recent averages, reinforcing the conviction behind the move. Any shallow pullbacks toward the breakout zone or previous consolidation highs can provide low-risk buying opportunities.
If the current structure continues, the next leg higher may test prior supply zones or unfilled gaps visible on the left side of the chart.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.